News

Skyphos to Showcase Additive Lithography at the Microfluidics Consortium Open Day in Boston

Skyphos Technologies, a Virginia Tech Corporate Research Center company advancing micro-scale and additive lithography manufacturing, will participate in the Microfluidics Consortium Open Day Meeting in Boston, where the company has been invited to present in the Physical Microfluidics Hotseat and deliver a tabletop demonstration.

The Microfluidics Consortium convenes worldwide leaders, from research and industry, bringing together stakeholders from materials, device development, instrumentation, and applications to accelerate adoption of microfluidics-enabled products and services. The Boston meeting is part of the consortium’s international event series and is organized around expert talks, startup hot-seat pitches, live demonstrations, and face-to-face networking.

At the event, Skyphos will highlight its advanced micro-fabrication platform and vertically integrated approach, aimed at enabling scalable, high-precision production of microdevice architectures outside of the clean room at scale. Skyphos specializes in components and process development relevant to lab-on-a-chip systems and related applications.

Participation in the Physical Microfluidics Hot-Seat places Skyphos alongside emerging companies and thought leaders presenting new approaches in the fields of diagnostics, therapeutics, organ-on-chip, synthetic biology, and next-generation microfluidic systems. The consortium’s broader mission is to connect participants from across Europe, the United States, and Asia to help move promising microfluidics technologies from concept toward commercial use.

“Skyphos is building manufacturing infrastructure for the next generation of microfluidic devices,” said Elliot McAllister- Founder. “This invitation to Boston reflects a growing recognition that scalable microfabrication remains a key bottleneck to the field. Skyphos and others are showing that new manufacturing models can translate and grow strong techniques and applications. Getting cures from lab to fab.”

Located within the Virginia Tech Corporate Research Center community, Skyphos represents the kind of deep-tech company the CRC was built to support: a venture combining advanced engineering, research-driven innovation, and commercial ambition. The company’s participation in Boston underscores the reach of Virginia-based innovation in emerging sectors where manufacturing and life sciences intersect.

 

Recent News

08/25/2026

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug Application (NDA) for ralinepag to treat PAH. The FDA has set a Prescription Drug User Fee Act target action date of June 24, 2027. Ralinepag has not been approved for use in any indication by the

08/19/2026

ATCC Receives New CDC Award to Advance Influenza Testing and Surveillance

ATCC has been selected by the Centers for Disease Control and Prevention (CDC) for a new contract to support serological assays for the detection and characterization of influenza viruses. The award, valued at up to $7.3 million over the 5-year contract period (contract 75D30126C21030), will support CDC’s National Center for Immunization and Respiratory Diseases, Influenza

08/18/2026

Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients